Marks Group Wealth Management Inc Buys 1,623 Shares of Stryker Co. (NYSE:SYK)

Marks Group Wealth Management Inc boosted its position in Stryker Co. (NYSE:SYK) by 3.2% in the third quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 52,936 shares of the medical technology company’s stock after purchasing an additional 1,623 shares during the period. Stryker makes up about 1.8% of Marks Group Wealth Management Inc’s portfolio, making the stock its 3rd largest holding. Marks Group Wealth Management Inc’s holdings in Stryker were worth $19,124,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds have also recently added to or reduced their stakes in SYK. Geneva Partners LLC bought a new position in shares of Stryker during the 3rd quarter valued at about $1,435,000. Sentry Investment Management LLC lifted its stake in Stryker by 9.1% during the third quarter. Sentry Investment Management LLC now owns 1,605 shares of the medical technology company’s stock valued at $580,000 after purchasing an additional 134 shares during the last quarter. Greenwood Capital Associates LLC boosted its holdings in Stryker by 2.3% during the third quarter. Greenwood Capital Associates LLC now owns 22,964 shares of the medical technology company’s stock worth $8,296,000 after buying an additional 519 shares in the last quarter. FSM Wealth Advisors LLC grew its position in Stryker by 2.8% in the third quarter. FSM Wealth Advisors LLC now owns 1,888 shares of the medical technology company’s stock worth $682,000 after buying an additional 52 shares during the last quarter. Finally, Moloney Securities Asset Management LLC bought a new position in shares of Stryker in the third quarter valued at $1,133,000. 77.09% of the stock is owned by institutional investors.

Stryker Stock Up 0.8 %

SYK opened at $369.86 on Wednesday. The company has a market capitalization of $141.00 billion, a PE ratio of 39.64, a price-to-earnings-growth ratio of 2.77 and a beta of 0.91. The business has a 50-day moving average of $360.66 and a 200-day moving average of $344.95. Stryker Co. has a fifty-two week low of $266.93 and a fifty-two week high of $374.63. The company has a debt-to-equity ratio of 0.66, a current ratio of 1.91 and a quick ratio of 1.22.

Stryker (NYSE:SYK) last posted its earnings results on Tuesday, October 29th. The medical technology company reported $2.87 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $2.77 by $0.10. Stryker had a net margin of 16.34% and a return on equity of 23.07%. The firm had revenue of $5.49 billion during the quarter, compared to analysts’ expectations of $5.37 billion. During the same period in the previous year, the company earned $2.46 earnings per share. The company’s revenue was up 11.9% compared to the same quarter last year. Equities research analysts forecast that Stryker Co. will post 12.06 EPS for the current fiscal year.

Analyst Ratings Changes

SYK has been the subject of several research reports. Royal Bank of Canada raised their price objective on Stryker from $386.00 to $400.00 and gave the stock an “outperform” rating in a research note on Wednesday, October 30th. Truist Financial increased their price target on Stryker from $370.00 to $380.00 and gave the company a “hold” rating in a research report on Wednesday, October 30th. Wolfe Research initiated coverage on Stryker in a report on Tuesday, September 10th. They set an “outperform” rating and a $405.00 price objective on the stock. BTIG Research raised their target price on shares of Stryker from $383.00 to $394.00 and gave the stock a “buy” rating in a report on Wednesday, October 30th. Finally, Wells Fargo & Company boosted their price target on shares of Stryker from $381.00 to $405.00 and gave the company an “overweight” rating in a report on Wednesday, October 30th. Four analysts have rated the stock with a hold rating and seventeen have given a buy rating to the company’s stock. According to MarketBeat, Stryker presently has a consensus rating of “Moderate Buy” and an average price target of $393.65.

Insider Activity at Stryker

In other Stryker news, VP M Kathryn Fink sold 7,347 shares of the firm’s stock in a transaction dated Tuesday, September 17th. The stock was sold at an average price of $366.98, for a total transaction of $2,696,202.06. Following the transaction, the vice president now directly owns 10,042 shares in the company, valued at $3,685,213.16. This trade represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. In other news, VP M Kathryn Fink sold 7,347 shares of Stryker stock in a transaction that occurred on Tuesday, September 17th. The shares were sold at an average price of $366.98, for a total value of $2,696,202.06. Following the transaction, the vice president now owns 10,042 shares of the company’s stock, valued at $3,685,213.16. This trade represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, insider Viju Menon sold 600 shares of the company’s stock in a transaction on Tuesday, August 27th. The stock was sold at an average price of $355.00, for a total transaction of $213,000.00. Following the sale, the insider now directly owns 9,069 shares of the company’s stock, valued at approximately $3,219,495. This represents a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last 90 days, insiders sold 10,068 shares of company stock valued at $3,693,972. Insiders own 5.50% of the company’s stock.

Stryker Profile

Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. The Orthopaedics and Spine segment provides implants for use in total joint replacements, such as hip, knee and shoulder, and trauma and extremities surgeries.